Copyright
©The Author(s) 2020.
World J Psychiatr. Aug 19, 2020; 10(8): 175-186
Published online Aug 19, 2020. doi: 10.5498/wjp.v10.i8.175
Published online Aug 19, 2020. doi: 10.5498/wjp.v10.i8.175
HVs, n = 18 | Patients, n = 22 | |
Age in yr | 18.9 ± 1.2 | 17.1 ± 2.3 |
Gender, male/female | 4/14 | 4/18 |
BMI in kg/m2 | 23.2 ± 2.1 | 23.1 ± 2.1 |
Education in yr | 12.9 ± 1.2 | 11.5 ± 2.6 |
Family history, yes/no | 3/15 | 8/14 |
First episode | N/A | 8 |
Recurrent episode | N/A | 14 |
Chemokine serum levels, pg/mL | HVs | Adolescents with MDD | Post hoc statistical analysis | ||||
n = 18 | 0 wk, n = 22 | 4 wk, n = 22 | 8 wk, n = 22 | 0 wk vs HVs | 4 wk vs 0 wk | 8 wk vs 0 wk | |
MCP-1 or CCL2 | 48.1 ± 3.7 | 107.7 ± 31.0 | 89.8 ± 19.9 | 102.9 ± 14.0 | dP < 0.0001 | aP < 0.05 | NS |
MIP-1α or CCL3 | 5.4 ± 1.0 | 7.3 ± 1.4 | 6.7 ± 1.4 | 7.4 ± 1.0 | dP < 0.0001 | NS | NS |
MIP-1β or CCL4 | 204.7 ± 42.2 | 324.0 ± 61.5 | 311.8 ± 48.1 | 294.8 ± 34.8 | dP < 0.0001 | NS | NS |
IL-8 or CXCL8 | 50.2 ± 6.8 | 79.2 ± 18.0 | 66.9 ± 13.2 | 73.3 ± 9.1 | dP < 0.0001 | NS | NS |
IP-10 or CXCL10 | 1890.0 ± 52.7 | 2309.0 ± 545.1 | 2224.0 ± 578.5 | 2710.0 ± 220.1 | aP < 0.05 | NS | aP < 0.05 |
Eotaxin or CCL11 | 255.4 ± 50.4 | 319.8 ± 65.5 | 277.2 ± 51.8 | 328.6 ± 50.7 | bP < 0.01 | NS | NS |
Clinical psychiatric scale | |||||||
HDRS | N/A | 19.4 ± 4.7 | 9.1 ± 4.72 | 6.0 ± 2.4 | N/A | dP < 0.0001 | dP < 0.0001 |
- Citation: de la Peña FR, Cruz-Fuentes C, Palacios L, Girón-Pérez MI, Medina-Rivero E, Ponce-Regalado MD, Alvarez-Herrera S, Pérez-Sánchez G, Becerril-Villanueva E, Maldonado-García JL, Jiménez-Martínez MC, Pavón L. Serum levels of chemokines in adolescents with major depression treated with fluoxetine. World J Psychiatr 2020; 10(8): 175-186
- URL: https://www.wjgnet.com/2220-3206/full/v10/i8/175.htm
- DOI: https://dx.doi.org/10.5498/wjp.v10.i8.175